<DOC>
	<DOCNO>NCT00322764</DOCNO>
	<brief_summary>The primary purpose study determine safety efficacy oral RG2417 ( Uridine ) administer patient Bipolar I depression twice daily six week .</brief_summary>
	<brief_title>Phase II Study Assess RG2417 Treatment Bipolar I Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<criteria>1 . DSMIVTR diagnosis Bipolar I Depression 2 . 18 65 year age , inclusive 3 . Depressive phase , measure MADRS great equal 20 Screening Day1 4 . Duration current depressive episode least four week Day 1 5 . Competent give inform consent 1 . Manic/hypomanic/mixed episode determine MINI Screening and/or Young Mania Rating Scale ( YMRS ) score &gt; 12 Screening and/or Day 1 2 . Dementia current Axis I diagnosis ( exclude bipolar I ) require pharmacological treatment 3 . A history alcohol substance dependence within six month Day 1 , history alcohol substance abuse within three month Day 1 4 . Urine drug screen positive amphetamine , cocaine metabolite , opiates and/or phencyclindine ( PCP ) 5 . An Axis II diagnosis likely interfere protocol compliance 6 . Initiation increase psychotherapy within 4 week Screening 7 . Psychotropic medication ( exclude fluoxetine ) within 24 hour initiation study drug Day 1 ; fluoxetine within 2 week initiation study drug Day 1 8 . Serious suicidal homicidal risk determine investigator and/or score &gt; 5 suicide item # 10 MADRS Screening and/or Day 1 9 . History sensitivity ingredient study drug 10 . Clinically significant abnormality screen laboratory result 11 . Clinically significant organic disease , include cardiovascular , endocrine , hepatic , pulmonary , neurologic , renal disease , medical condition , serious intercurrent illness , extenuate circumstance , opinion investigator , would interfere performance interpretability , put patient risk , study procedure 12 . Women pregnant , breastfeeding , refuse use adequate birth control 13 . Current seizure disorder 14 . Participation investigational drug study within twentyeight day Day 1 15 . Current psychotic episode 16 . Clozaril use and/or electroconvulsive therapy within six month Day 1 17 . Failure three adequate trial standard therapy depression current episode 18 . Current episode depression longer one year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>manic depression</keyword>
	<keyword>bipolar disorder</keyword>
	<keyword>depression</keyword>
	<keyword>uridine</keyword>
	<keyword>RG2417</keyword>
</DOC>